A Mourad1, S Straube2, S Armijo-Olivo3, R Gniadecki4. 1. Faculty of Medicine & Dentistry, University of Alberta Medical School, Edmonton, AB, Canada. 2. Division of Preventive Medicine, University of Alberta, Edmonton, AB, Canada. 3. Research Center, Faculty of Rehabilitation Medicine, University of Alberta, Edmonton, AB, Canada. 4. Division of Dermatology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Abstract
BACKGROUND: Long-term therapy for psoriasis is impaired by gradual loss of effectiveness and treatment discontinuation. Identifying factors that affect biologic drug survival may help in treatment optimization. OBJECTIVES: To identify factors that predicted biologic drug persistence or discontinuation in a real-life setting. METHODS: We identified studies of biologic persistence in psoriasis through a comprehensive, systematic literature search using predefined search criteria. Studies were screened by title and abstract then further by full-text review. Hazard ratio (HR) data were extracted for all available predictive factors (HRs > 1 denoted biologic discontinuation, and HRs < 1 denoted biologic persistence). A meta-analysis of HRs (random-effects model) was used to assess any predictive factor included in at least two studies. RESULTS: Sixteen cohort studies were included in the review, with a total of 32 194 patients. A meta-analysis was performed on 13 studies (n = 29 802): nine for female sex (n = 28 090), six for obesity (n = 9311) and six for psoriatic arthritis (n = 24 444). Obesity and female sex predicted treatment discontinuation, with HRs of 1.21 [95% confidence interval (CI) 1.10-1.32, I2 = 0%] and 1.22 (95% CI 1.07-1.38, I2 = 84%), respectively. Concomitant psoriatic arthritis predicted biologic persistence (HR 0.83, 95% CI 0.80-0.86, I2 = 0%). Female sex predicted biologic discontinuation due to side-effects, with a pooled HR of 2.16 (95% CI 1.39-3.35, I2 = 67%). Other reported predictive factors (smoking, metabolic syndrome, biologic naivety, age, Dermatology Life Quality Index, dyslipidaemia, high socioeconomic status and concomitant methotrexate) were insufficiently reported for meta-analysis. CONCLUSIONS: Our meta-analysis demonstrates that female sex and obesity predict biologic discontinuation, and concomitant psoriatic arthritis predicts biologic survival. What's already known about this topic? Ineffectiveness is the main factor that causes drug discontinuation during long-term treatment of psoriasis. It is unclear which factors and comorbidities impact drug persistence. What does this study add? Female sex and obesity predict biologic discontinuation due to ineffectiveness and adverse events. Concomitant psoriatic arthritis is associated with improved drug persistence.
BACKGROUND: Long-term therapy for psoriasis is impaired by gradual loss of effectiveness and treatment discontinuation. Identifying factors that affect biologic drug survival may help in treatment optimization. OBJECTIVES: To identify factors that predicted biologic drug persistence or discontinuation in a real-life setting. METHODS: We identified studies of biologic persistence in psoriasis through a comprehensive, systematic literature search using predefined search criteria. Studies were screened by title and abstract then further by full-text review. Hazard ratio (HR) data were extracted for all available predictive factors (HRs > 1 denoted biologic discontinuation, and HRs < 1 denoted biologic persistence). A meta-analysis of HRs (random-effects model) was used to assess any predictive factor included in at least two studies. RESULTS: Sixteen cohort studies were included in the review, with a total of 32 194 patients. A meta-analysis was performed on 13 studies (n = 29 802): nine for female sex (n = 28 090), six for obesity (n = 9311) and six for psoriatic arthritis (n = 24 444). Obesity and female sex predicted treatment discontinuation, with HRs of 1.21 [95% confidence interval (CI) 1.10-1.32, I2 = 0%] and 1.22 (95% CI 1.07-1.38, I2 = 84%), respectively. Concomitant psoriatic arthritis predicted biologic persistence (HR 0.83, 95% CI 0.80-0.86, I2 = 0%). Female sex predicted biologic discontinuation due to side-effects, with a pooled HR of 2.16 (95% CI 1.39-3.35, I2 = 67%). Other reported predictive factors (smoking, metabolic syndrome, biologic naivety, age, Dermatology Life Quality Index, dyslipidaemia, high socioeconomic status and concomitant methotrexate) were insufficiently reported for meta-analysis. CONCLUSIONS: Our meta-analysis demonstrates that female sex and obesity predict biologic discontinuation, and concomitant psoriatic arthritis predicts biologic survival. What's already known about this topic? Ineffectiveness is the main factor that causes drug discontinuation during long-term treatment of psoriasis. It is unclear which factors and comorbidities impact drug persistence. What does this study add? Female sex and obesity predict biologic discontinuation due to ineffectiveness and adverse events. Concomitant psoriatic arthritis is associated with improved drug persistence.
Authors: Tiago Torres; Luis Puig; Ron Vender; Jensen Yeung; José-Manuel Carrascosa; Stefano Piaserico; Paolo Gisondi; Charles Lynde; Paulo Ferreira; Pedro Mendes Bastos; Esteban Dauden; Luiz Leite; Joana Valerio; Elena Del Alcázar-Viladomiu; Eva Vilarrasa Rull; Mar Llamas-Velasco; Federico Pirro; Francesco Messina; Manfredo Bruni; Gaetano Licata; Federica Ricceri; Alessia Nidegger; Jan Hugo; Asfandyar Mufti; Athina-Ioanna Daponte; Laetitia Teixeira; Anna Balato; Marco Romanelli; Francesca Prignano; Spyridon Gkalpakiotis; Curdin Conrad; Elizabeth Lazaridou; Natalia Rompoti; Marina Papoutsaki; Miguel Nogueira; Andrea Chiricozzi Journal: Am J Clin Dermatol Date: 2022-08-17 Impact factor: 6.233
Authors: Thomas Graier; Wolfgang Weger; Paul-Gunther Sator; Wolfgang Salmhofer; Barbara Gruber; Constanze Jonak; Claudia Kölli; Martina Schütz-Bergmayr; Igor Vujic; Gudrun Ratzinger; Nina Häring; Clemens Painsi; Knut Prillinger; Alexander Mlynek; Hans Skvara; Hannes Trattner; Adrian Tanew; Roland Lichem; Christina Ellersdorfer; Franz Legat; Alexandra Gruber-Wackernagel; Angelika Hofer; Erich Schmiedberger; Wolfram Hoetzenecker; Robert Müllegger; Werner Saxinger; Franz Quehenberger; Peter Wolf Journal: JAAD Int Date: 2020-12-26
Authors: Francesco Bellinato; Paolo Gisondi; Elena Mason; Paolo Ricci; Martina Maurelli; Giampiero Girolomoni Journal: Dermatol Ther (Heidelb) Date: 2022-04-27
Authors: Carlos Pelayo Hernández-Fernández; Gregorio Carretero; Raquel Rivera; Carlos Ferrándiz; Esteban Daudén; Pablo de Cueva; Isabel Belinchón; Francisco Javier Gómez-García; Enrique Herrera-Acosta; Diana P Ruiz-Genao; Marta Ferrán; Mercé Alsina; Ofelia Baniandrés-Rodríguez; José Luis Sánchez-Carazo; Rafael Botella-Estrada; Antonio Sahuquillo-Torralba; Lourdes Rodríguez; Jaime Vilar-Alejo; Carmen García-Donoso; José M Carrascosa; Mar Llamas-Velasco; Enrique Herrera-Ceballos; Jose Luis López-Estebaranz; Conrad Pujol-Marco; Miguel Angel Descalzo; Ignacio Garcia-Doval Journal: Acta Derm Venereol Date: 2021-01-04 Impact factor: 3.875